Senti Biosciences is trading 7.3% up at $0.20, though the move’s specific catalyst remains uncertain. - The company disclosed that October 30, 2026, is the record date for its previously announced CVR distribution. - Director Edward Mathers resigned, effective October 27. - Biotech-sector strength is supporting context, but the broader market is little changed; reporting does not establish the updates as direct drivers of the October 28 move.